- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
ACL
ASX
Week ended 07 Aug 2026
Weekly Investor Report
Australian Clinical Labs Limited · Healthcare · Diagnostics & Research
Latest close
2.38 AUD
0.0%
latest week
Weekly setup
Mixed setup
The weekly trend is not active. Price is 8.5% above the Trend Line and sits at 50.4% of its 52-week range. The latest completed week returned 0.0%, after a 7.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
48
out of 100
Latest Close
2.38 AUD
7 Aug 2026
1W Return
0.0%
latest completed week
4W Return
7.2%
short-term follow-through
12W Return
25.6%
quarterly tape
Trend Breadth
13.5%
7 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.0%
Latest completed week; four-week move 7.2%.
Indicator stack
7/76
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Recent
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
18 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is 8.5% above the Trend Line and sits at 50.4% of its 52-week range. The latest completed week returned 0.0%, after a 7.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.4212-week average 0.20
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.42Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 7.2% over four weeks, 25.6% over 12 weeks, and -11.0% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year7
Trend breadth13.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.21Latest activity-pressure read.
Pressure change52.4%Four-week change in activity pressure.
Leadership-4.41Latest relative-leadership reading.
RS change39.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks strongly; valuation is inexpensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2025
Field coverage 85%
Model confidence 43%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength86/100Blend of value, momentum, and quality. Underlying universe rank 15; rank 1 is best.
Value95/100Relative valuation strength. Underlying universe rank 6; rank 1 is best.
Quality98/100Profitability and accounting quality. Underlying universe rank 3; rank 1 is best.
Momentum13/100Medium-term price momentum. Underlying universe rank 88; rank 1 is best.
Growth89/100Revenue and earnings growth. Underlying universe rank 12; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework74/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 13.7x Price divided by trailing earnings.
- Price / sales
- 0.6x Market value relative to trailing revenue.
- EV / EBITDA
- 3.8x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 24.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 82.6% Gross profit retained from each unit of revenue.
- Operating margin
- 8.5% Operating profit retained from revenue.
- Free-cash-flow margin
- 23.7% Free cash flow generated from revenue.
- Return on invested capital
- 10.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 6.7% Latest one-year revenue growth.
- EPS growth
- 39.7% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 13.9% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 5.4% Cash dividends relative to market value.
- Buyback yield
- 4.3% Net share repurchases relative to market value.
- Shareholder yield
- 9.7% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 18 relevant articles.
3 positive · 12 neutral · 3 negativePatient CapitalRecent
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-18.4%Distance below the 52-week high.
13-week volatility2.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2610 weeks finished lower.
Best week+6.3%Week of 17 Jul.
Worst week-6.9%Week of 24 Apr.
Latest week+0.0%Week of 7 Aug.
Shape of recent returns
Strong gains3
Modest gains10
Flat weeks3
Modest losses5
Sharp losses5
Recent vol2.4%13-week weekly-return volatility.
Base vol4.2%52-week weekly-return volatility.
Up/down split24/24Count of positive and negative weeks in the 52-week window.
Average skew3.3% / -3.6%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorAU Healthcare
4-week rank23 / 100
Group average-0.9%
Trend breadth25.0%
Trend25.0%active weekly trend signals
MD58.0%positive activity pressure
RS26.0%positive relative leadership
Four-week leaders
IndustryAU Diagnostics & Research
4-week rank5 / 14
Group average2.1%
Trend breadth14.3%
Trend14.3%active weekly trend signals
MD50.0%positive activity pressure
RS14.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape40/100
Trend, activity pressure, participation, and risk combine to a 40/100 tape read.
Indicator analysis32/100Latest 12-week confirmation: trend 0/12, activity pressure 9/12, relative leadership 0/12.
Activity pressure 0.42; No reversal markers Factors74/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 2; Small Cap Core rank 7 SVQF74/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 67.0 of 257 Patient CapitalRecentActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks Sentiment50/100Weighted news tone is neutral across 18 relevant articles.
Citigroup Reports Initial Substantial Holding of 5.04% in Australian Clinical Labs Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 2.38 AUD | 0.0% | 2.19 AUD | 2.61 AUD | 1.21 | -4.41 | 1.7M | Off |
| 31 Jul 2026 | 2.38 AUD | 3.0% | 2.20 AUD | 2.61 AUD | 1.19 | -1.68 | 2.4M | Off |
| 24 Jul 2026 | 2.31 AUD | -2.1% | 2.21 AUD | 2.62 AUD | 1.05 | -2.58 | 2.4M | Off |
| 17 Jul 2026 | 2.36 AUD | 6.3% | 2.22 AUD | 2.62 AUD | 0.97 | -1.08 | 3.7M | Off |
| 10 Jul 2026 | 2.22 AUD | -0.9% | 2.23 AUD | 2.62 AUD | 0.79 | -7.32 | 3.5M | Off |
| 3 Jul 2026 | 2.24 AUD | 0.9% | 2.25 AUD | 2.63 AUD | 0.62 | -7.24 | 296.0K | Off |
| 26 Jun 2026 | 2.22 AUD | 1.4% | 2.27 AUD | 2.63 AUD | 0.51 | -7.62 | 605.3K | Off |
| 19 Jun 2026 | 2.19 AUD | 1.4% | 2.29 AUD | 2.64 AUD | 0.31 | -9.91 | 661.1K | Off |
| 12 Jun 2026 | 2.16 AUD | 4.9% | 2.31 AUD | 2.64 AUD | 0.06 | -11.17 | 271.7K | Off |
| 5 Jun 2026 | 2.06 AUD | 1.5% | 2.32 AUD | 2.64 AUD | -0.29 | -13.88 | 2.4M | Off |
| 29 May 2026 | 2.03 AUD | 3.0% | 2.34 AUD | 2.65 AUD | -0.67 | -16.58 | 535.4K | Off |
| 22 May 2026 | 1.97 AUD | 4.0% | 2.36 AUD | 2.65 AUD | -0.89 | -18.84 | 3.0M | Off |
| 15 May 2026 | 1.90 AUD | -1.3% | 2.38 AUD | 2.66 AUD | -1.08 | -22.27 | 3.8M | Off |
| 8 May 2026 | 1.92 AUD | 0.0% | 2.40 AUD | 2.67 AUD | -1.00 | -22.99 | 2.8M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.